Core Viewpoint - A class action lawsuit has been filed against Quantum Biopharma Ltd. for alleged securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of shareholders of Quantum Biopharma Ltd. and is being handled by Pomerantz LLP [1]. - Investors have until February 23, 2026, to request to be appointed as Lead Plaintiff if they purchased Quantum securities during the Class Period [2]. Group 2: Allegations Against Defendants - The complaint alleges that several financial institutions, including CIBC World Markets and RBC Capital Markets, engaged in manipulative trading practices by placing thousands of spoofed sell orders [4]. - These spoofed orders created a false impression of Quantum's stock price declining, leading other investors to sell their shares at artificially low prices [4]. - After driving the stock price down, the defendants purchased shares at these depressed levels to profit from the manipulation [4]. Group 3: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud [5]. - The firm has a track record of recovering multimillion-dollar damages for class members over its 85-year history [5].